Lung Cancer
Show Only Open Trials
1.
CALGB 30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
- Study Status: Closed to Enrollment
- Sponsor: CALGB
- Disease Status and/or Stage: Non Small Cell Lung Cancer (NSCLC)
- Protocol ID: CALGB 30801
2.
A Phase 1a/b Non-Randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile Compound 31510 (Ubidecarenone, USP) Nanosuspension for Injection Administered Intravenously to Patients with Solid Tumors
- Study Status: Open to Enrollment
- Sponsor: Berg Pharma
- Disease Status and/or Stage: Advanced Solid Tumors
3.
Analysis of Hematopoietic Progenitor Cells and Endothelial Progenitor Cells to Predict Early Relapse of Treated Non-Small-Cell Lung Cancer (NSCLC): A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Non-Small Cell Lung Cancer
4.
LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy
- Study Status: Closed to Enrollment
- Sponsor: Boehringer Ingelheim Pharmaceuticals
- Disease Status and/or Stage: Previously Treated Advanced Squamous Cell Lung Cancer
5.
Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer
- Study Status: Open to Enrollment
- Sponsor: Immunomedics
- Disease Status and/or Stage: Metastatic Epithelial Cancer
6.
E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
- Study Status: Open to Enrollment
- Sponsor: Eastern Cooperative Oncology Group
7.
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy
- Study Status: Open to Enrollment
- Sponsor: Lilly
- Disease Status and/or Stage: Stage IV Non-Small Cell Lung Cancer
8.
A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination with either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
- Study Status: Open to Enrollment
- Sponsor: Tragara Pharmaceuticals
- Disease Status and/or Stage: Stage IIIB/IV or Recurrent, Unresectable Non-Small Cell Lung Cancer
9.
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer (PROCLAIM)
- Study Status: Open to Enrollment
- Sponsor: Eli Lily & Co.
- Disease Status and/or Stage: Unresectable, Locally Advance, Stage III Non-Small Cell Lung Cancer
10.
CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (<2cm) Peripheral Non-Small Cell Lung Cancer
- Study Status: Open to Enrollment
- Sponsor: Cancer and Leukemia Group B, National Cancer Institute
- Disease Status and/or Stage: Non-small Cell Lung Cancer
11.
A Phase II Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid and Islet Cell Cancer
- Study Status: Closed to Enrollment
- Sponsor: Mayo Clinic, National Cancer Institute
- Disease Status and/or Stage: Locally Advanced, Recurrant or Metastatic disease
12.
A Phase I Study of 177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-591) in Patients with Nonprostate Metastatic Solid Tumors: A Pilot Study
- Study Status: Open to Enrollment
- Sponsor: Weill Cornell Medical College
- Disease Status and/or Stage: Metastatic Solid Tumor
